MariMed Inc.
MRMD · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.13 | 0.03 | 0.11 | 0.22 |
| FCF Yield | -13.52% | -12.86% | -4.51% | 6.12% |
| EV / EBITDA | 9.02 | 14.81 | 5.65 | 9.57 |
| Quality | ||||
| ROIC | 5.19% | 21.64% | 10.73% | 8.73% |
| Gross Margin | 39.80% | 44.36% | 47.73% | 54.55% |
| Cash Conversion Ratio | -0.56 | -0.49 | 0.54 | 4.70 |
| Growth | ||||
| Revenue 3-Year CAGR | 5.63% | 6.95% | 38.09% | 38.62% |
| Free Cash Flow Growth | 54.17% | -136.57% | -131.41% | 1,206.51% |
| Safety | ||||
| Net Debt / EBITDA | 5.87 | 5.87 | 1.01 | -0.18 |
| Interest Coverage | 0.42 | 1.64 | 12.03 | 11.40 |
| Efficiency | ||||
| Inventory Turnover | 2.84 | 3.27 | 3.60 | 5.65 |
| Cash Conversion Cycle | 99.52 | 91.60 | 87.46 | 41.30 |